A Trial of SHR6508 in Secondary Hyperparathyroidism

Summary

The study is being conducted to evaluate the tolerability, pharmacokinetics and pharmacodynamics of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis

Timeline

Start

2022-03-10

Primary completion

2023-07-07

Completion

2023-08-02

Drugs

Indications